GIP receptor
Cell and pharmacology studies characterize agonist activity at the GIP receptor as one part of the compound's triple-receptor profile.
Product images are for illustrative reference only. Final label layout and packaging details may vary by batch or production run. Product identity, strength and batch-specific documentation are provided separately and remain product-specific.
NOREXA PEPTIDES / RESEARCH MATERIAL
Retatrutide20 mg
Lyophilized Peptide — Single vial
Retatrutide 20 mg supplied exclusively for laboratory research use. Batch documentation and independent third-party laboratory testing status are made accessible through the NOREXA batch verification system.
Retatrutide, referred to informally as Reta or R3TA in some online research discussions and identified in development literature as LY3437943, is presented here solely as a laboratory research material.
In stock
€150 per vial
Buy 3+ vials — Save 10%Buy 6+ vials — Save 15%Standard price
- RESEARCH FOCUS
- Weight & Metabolism
QUANTITY
Research areas
FOR LABORATORY RESEARCH USE ONLY.
VERIFY BATCH →Not for human or animal consumption.
Not intended to diagnose, treat, cure or prevent any disease.
RESEARCH & TECHNICAL OVERVIEW
Retatrutide
20 mg
Retatrutide (LY3437943) is a synthetic single-peptide analogue engineered for agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. It is not a naturally occurring peptide.
Published research has examined its multi-receptor pharmacology and metabolic effects in early-phase and phase 2 human studies. Those studies concern the investigational compound and do not test or endorse any NOREXA batch.
RESEARCH SCOPE
For research use only. Not for human or veterinary use. Published findings describe the compound or related research systems; they are not claims about this NOREXA batch.
HANDLING INFORMATION
Storage After
Reconstitution.
- Temperature
- Refrigerate at 2–8°C.
- Light
- Keep sealed and protected from light.
- Stability
- An exact post-reconstitution stability period has not been established for this formulation.
The cited reference does not establish an exact storage period for this product after reconstitution with bacteriostatic water.
MedChemExpress — Retatrutide technical record ↗SCIENTIFIC CONTEXT
Structured.
Source-led.
Longer technical information is grouped for easier reading on desktop and mobile.
01Natural Biological Context+
GIP, GLP-1 and glucagon are endogenous peptide hormones involved in nutrient sensing, pancreatic signalling and energy metabolism. Retatrutide is a synthetic analogue designed to combine activity at all three receptor systems in one molecule.
The engineered compound should not be described as naturally occurring merely because its receptor targets have endogenous ligands.
02Research Mechanisms+
GLP-1 receptor
Research evaluates GLP-1 receptor signalling within the same single-peptide architecture.
Glucagon receptor
Glucagon-receptor activity is investigated alongside incretin-receptor signalling rather than as a separate molecule.
Integrated metabolic signalling
Phase 1b and phase 2 studies have examined biomarkers and metabolic outcomes in humans; these data remain investigational and are not product-performance claims.
03Research Applications+
- Receptor pharmacology and comparative signalling assays involving GIPR, GLP-1R and GCGR.
- Laboratory investigation of multi-agonist peptide design and metabolic signalling.
- Published human research involving glucose regulation, energy balance and body-composition endpoints.
04Laboratory Research Preparation+
Lyophilized material may require preparation as a laboratory solution before use in an in-vitro assay. The solvent or buffer and working concentration should follow the applicable protocol and documentation for the exact molecular form.
This page intentionally provides no human dosing calculations, syringe-unit conversions, administration route or treatment schedule. Preparation conditions should be established and recorded by qualified laboratory personnel.
INDEPENDENT VERIFICATION
Batch evidence,
without overclaiming.
Purity alone is not enough. NOREXA distinguishes identity, purity and actual quantity, and publishes results only for the exact batch tested.
CURRENT BATCH / LOT
T20260501INDEPENDENT REPORT PUBLISHED
- Identity
- Verified Retatrutide confirmed
- Purity
- Verified 99.834%
- Quantity / content
- Verified 20.53 mg
- Product
- Retatrutide 20 mg
- Independent Laboratory
- Janoshik Analytical
- Laboratory Order
- #83933
- Verification Key
- B4WG4F745H1B
These results apply only to Retatrutide 20 mg, batch T20260501. They must not be transferred to another strength or lot.
HISTORICAL BATCHES
No historical batch records are currently published for this product.
PRODUCT INFORMATION
Technical
Data.
Verified identity and catalogue information for this NOREXA research material. Unconfirmed fields are omitted.
- Product Name
- Retatrutide
- Content
- 20 mg
- Form
- Lyophilized Peptide
- Presentation
- Single vial
- CAS Number
- 2381089-83-2
- Research Classification
- Research Use Only
Batch documentation and independent reports are shown only when published for the exact corresponding batch.
CHEMICAL IDENTITY REFERENCE ↗SELECTED SOURCES
Research
Literature.
Selected literature describes the compound and relevant research pathways; it does not constitute testing or endorsement of this NOREXA batch.
- 01Human research↗
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes
The Lancet · 2022
- 02Human research↗
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
- 03Human research↗
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
The Lancet · 2023
PRODUCT FAQ
Retatrutide
questions.
01Is Retatrutide naturally occurring?+
No. Retatrutide is a synthetic multi-receptor peptide analogue. Its receptor targets have endogenous ligands, but the engineered molecule itself is not naturally occurring.
02What receptor pathways are studied?+
Published work examines agonist activity at GIP, GLP-1 and glucagon receptors, including how those signals combine within one peptide.
03Does the literature verify this NOREXA vial?+
No. Literature describes the investigational molecule. Only batch-specific documentation shown in NOREXA verification applies to a NOREXA batch.
04What does research use only mean?+
The material is supplied for controlled laboratory and analytical work only. It is not for human or veterinary use, ingestion or administration.
SECTION 01 — STANDARDS
Scientific transparency,
documented for research.
01 / 03Scientific Integrity
Independent analytical results are presented as reported by the testing laboratory, without altering the laboratory’s findings.
02 / 03Batch Traceability
Each batch is assigned a record linking the product to its available technical and independent testing documentation.
03 / 03Quality Documentation
Available batch documentation is organized under the corresponding batch number for clear reference.